SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SC again asks Novartis to slash cancer drug price

13 Sep 2012 Evaluate

Reasoning that the company's scheme for providing the drug free to poor patients was complicated, the Supreme Court on Wednesday once again urged pharma company Novartis to scale down the price of its cancer drug Glivec, made from compound imatinib mesylate.

Further, apex court bench of Justice Aftab Alam and Justice Ranjana Prakash Desai, besides reasoning the scheme to be complicated, also averred that the end result of the any commercial venture was profit or loss and that Novartis' business transactions meant financial results.

Novartis filed an affidavit in pursuance to a query by the court on Tuesday whether the pharma company would continue with its scheme of providing free or subsidised medicine to poor and needy patients if it was granted patent of Glivec.

The court on Tuesday said that cost of Rs 1.2 lakh per month, charged by the company, is too high to afford a treatment. Further, taking a dig at the huge cost of the drug, the bench even remarked in a lighter vein that the cost was perhaps exorbitant even for the apex court judge.

Glivec is the trade name of chemical beta crystalline form of imatinib mesylate compound which is used for the treatment of chronic myeloid leukemia (CML) and malignant gastrointestinal stromal tumors. Further, the medicine which was being marketed by the trade name of “Gleevec” had been patented in 35 countries including by the US.

Novartis Share Price

994.40 -5.30 (-0.53%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Redington 234.90
Adani Enterprises 2218.35
Amrapali Industries 17.53
Rashi Peripheral 455.25
PDS 301.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×